A new year brings new breakthroughs — and 2026 is already setting the stage for faster, smarter, and more connected clinical research. From regulatory milestones to regional growth and operational innovation, this edition highlights what’s driving progress in early-phase development: RevBio receives
first-in-human · clinical research · regulatory · FDA · MedTech · biopharma
A new year brings new breakthroughs — and 2026 is already setting the stage for faster, smarter, and more connected clinical research. From regulatory milestones to regional growth and operational innovation, this edition highlights whats driving progress in early-phase development: RevBio receives FDA approval for its regenerative bone glue trial. Akari advances a novel ADC therapy to first-in-human testing. Abbott gains FDA clearance for a next-generation cardiac system. Croatia strengthens its position as a Balkan trial hub.Begin the year energized by discoveries redefining the future of Medtech and Biopharma. 👇
RevBio has received FDA approval to initiate a dental clinical trial for its regenerative bone adhesive, Tetranite®. The biomaterial is engineered to mimic natural bone, bonding quickly to tissue while stimulating regeneration—a potential game changer for bone restoration in dental and orthopedic applications.
The upcoming study will evaluate safety and performance in patients requiring bone grafting during dental implant procedures. If successful, this innovation could simplify surgeries, shorten recovery times, and expand treatment options for patients with compromised bone health.
Key Points:
Akari Therapeutics is preparing to launch its first-in-human clinical trial for a novel antibody-drug conjugate (ADC) payload designed to improve precision in cancer treatment. The therapy aims to combine targeted antibody delivery with a next-generation payload that enhances efficacy while reducing off-target toxicity.
Highlights:
As investment in advanced biologics continues to rise, Akaris progress illustrates how translational science is accelerating the path from lab discovery to early clinical validation.
Does Your Company Need Accelerated First-in-Human Clinical Trial Results?
Overcome the complex landscape of first-in-human clinical trials with confidence. Whether youre advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Leverage 20+ years of expertise across Medtech, Biopharma, and Radiopharma first-in-human trials Navigate Latin Americas regulatory environment and access high-quality research sites Get tailored support for study design, approvals, site selection, and patient recruitment Bring your innovations to market faster with Latin Americas first-in-human trial experts.
Schedule Your First-in-Human Trial Consult
Abbott has received FDA approval for its Volt™ Pulsed Field Ablation (PFA) system, a breakthrough technology designed to treat atrial fibrillation through precise, non-thermal energy delivery. The system targets heart tissue with improved safety and accuracy, reducing the risk of damage to nearby structures and shortening procedure times.
The approval marks a pivotal step in the evolution of cardiac electrophysiology, as PFA emerges as one of the most promising innovations in arrhythmia treatment. Abbotts entry into this space highlights the growing global shift toward safer, faster, and more effective energy-based therapies that redefine standards in cardiovascular care.
As decentralized and hybrid studies expand, clinical supply operations have become a defining factor in trial success. Coordinating shipments, ensuring product integrity, and managing data across global sites now require seamless integration between logistics and technology.
Key Points:
Decentralized trials depend on efficiency at every step—and clinical supply chain innovation is proving essential in sustaining that momentum.
Croatia is quickly emerging as a strategic hub for early-phase drug trials in Eastern Europe. Its efficient regulatory environment, experienced investigators, and cost-effective infrastructure make it an attractive destination for Biopharma and Medtech sponsors looking to expand their global research footprint. Strategic planning around site selection, logistics, and local partnerships has become critical to ensure trial efficiency and regulatory compliance in the region.
Why It Matters:
The U.S. FDA is testing a new contracting approach designed to accelerate the development of technologies that advance public health. By introducing more flexible and collaborative agreements, the agency aims to streamline partnerships with innovators, small businesses, and research institutions working on breakthrough medical solutions.
The initiative reflects the FDAs broader goal of fostering innovation through modernized infrastructure and faster engagement with private-sector partners. This model could help bridge the gap between early research and real-world application, particularly for emerging Medtech and Biopharma companies.
Bottom Line:
← All Global Trial Accelerators editions · Contact bioaccess®